Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Oxytocin as Enhancer of Psychotherapy Outcomes in Severe Mental Illness
NCT03566069Phase 2Active, not recruiting
- Sponsor
- Shalvata Mental Health Center
- Start
- Jun 2018
- Primary completion
- Jun 2025
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of oxytocin nasal spray in anxiety disorder, major depressive disorder (MDD), obsessive compulsive disorder (OCD) and 2 more (2 arms), sponsored by Shalvata Mental Health Center. Primary endpoint: Change in Depression and Anxiety Symptoms. Started Jun 2018; status: active, not recruiting.
02
Drugs
oxytocin nasal spray
03
Conditions
anxiety disordermajor depressive disorder (MDD)obsessive compulsive disorder (OCD)personality disorderspost-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT03566069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03566069.